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Traumatic brain injury (TBI) and subarachnoid hemorrhage (SAH) are major contributors 
to morbidity and mortality. Following the initial insult, patients may deteriorate due to 
secondary brain damage. The underlying molecular and cellular cascades incorporate 
components of the innate immune system. There are different approaches to assess and 
monitor cerebral inflammation in the neuro intensive care unit. The aim of this narrative 
review is to describe techniques to monitor inflammatory activity in patients with TBI 
and SAH in the acute setting. The analysis of pro- and anti-inflammatory cytokines in 
compartments of the central nervous system (CNS), including the cerebrospinal fluid 
and the extracellular fluid, represent the most common approaches to monitor surrogate 
markers of cerebral inflammatory activity. Each of these compartments has a distinct 
biology that reflects local processes and the cross-talk between systemic and CNS 
inflammation. Cytokines have been correlated to outcomes as well as ongoing, second-
ary injury progression. Alongside the dynamic, focal assay of humoral mediators, imag-
ing, through positron emission tomography, can provide a global in vivo measurement of 
inflammatory cell activity, which reveals long-lasting processes following the initial injury. 
Compared to the innate immune system activated acutely after brain injury, the adaptive 
immune system is likely to play a greater role in the chronic phase as evidenced by 
T-cell-mediated autoreactivity toward brain-specific proteins. The most difficult aspect 
of assessing neuroinflammation is to determine whether the processes monitored are 
harmful or beneficial to the brain as accumulating data indicate a dual role for these 
inflammatory cascades following injury. In summary, the inflammatory component of the 
complex injury cascade following brain injury may be monitored using different modali-
ties. Using a multimodal monitoring approach can potentially aid in the development of 
therapeutics targeting different aspects of the inflammatory cascade and improve the 
outcome following TBI and SAH.
Keywords: neuroinflammation, traumatic brain injury, subarachnoid hemorrhage, multimodal monitoring, 
secondary brain injury
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iNTRODUCTiON
Pathophysiology of Brain injury
Traumatic brain injury (TBI) and aneurysmal subarachnoid 
hemorrhage (SAH) are common neurological conditions (1, 2) 
associated with extensive morbidity and mortality (3, 4). While 
the two diseases are different entities, they share many common 
features in their secondary pathophysiology. Furthermore, they 
provide an experimental paradigm in which multimodality 
monitoring offers the opportunity to decipher common patho-
logical processes. There are multiple potential mechanisms by 
which neuronal injury is inflicted following TBI and SAH. The 
traditional clinical paradigm for management of these conditions 
has focused on adequate delivery of oxygen and appropriate 
metabolic substrates to the injured brain, and prevention of 
secondary injuries caused by hypotension and hypoxia (5). 
These secondary processes lead to an increasingly inhospitable 
environment with ongoing excitotoxicity, oxidative stress, blood–
brain barrier (BBB) disruption, cortical spreading depression, 
mitochondrial dysfunction, and subsequent cellular death in the 
tissue surrounding the initial damage (6, 7). There is an increas-
ing recognition that inflammatory mediators are involved in the 
mechanistic link that underlies these injurious processes (8–10).
what is Neuroinflammation?
Galen’s original description of inflammation as calor (heat), 
dolor (pain), rubor (redness), tumor (swelling), and subsequently 
functio laesa (loss of function) has been refined into a more 
complex phenomenon that represents the host response to any 
insult. This complex process involves the release of molecular 
mediators, the alteration of the cerebral vasculature, the activa-
tion and influx of immune cells to eliminate pathogens, damaged 
cells, and other perceived harmful stimuli. The brain was long 
thought to be immunoprivileged due to the presence of the BBB, 
which limits the cross-talk between the blood and brain-resident 
inflammatory cells, the lack of a classical lymphatic system, 
and the shielding of neural antigens from peripheral immune 
surveillance. More recently, all these assumptions have been 
questioned and revised (11). There is an increasing realization 
that cerebral inflammation or neuroinflammation occurs within 
the whole gamut of central nervous system (CNS) pathologies, 
whether it is an adaptive autoimmune response (e.g., multiple 
sclerosis) or a response to external stimuli (e.g., accumulation 
of red blood cells following brain hemorrhage). While micro-
glia are considered the primary immune cells of the CNS, it is 
becoming increasingly clear that other glial cells (astrocytes and 
oligodendrocytes) as well as neurons display immune-competent 
functions. Activated resident cells of the CNS, in combination 
with migrating inflammatory cells from peripheral blood, form 
an intricate immune network (12, 13). Although this immune 
response may be initiated to protect the brain, it is becoming 
evident that it can result in harmful outcomes for the CNS (14). 
In fact, an ongoing neuroinflammatory response may not only 
contribute to increased edema, cellular death, and BBB disrup-
tion but also function as a potent scavenger of dead cells and sup-
port the regenerative processes in the injured CNS (15, 16). An 
outline of the pathophysiological mechanisms identified in the 
literature is illustrated in Figure 1, many of which are described 
in this review.
Aspects of Neuroinflammation in SAH
Brain hemorrhage triggers a series of pathological processes 
resulting in neuronal damage and consequent neurological deficit 
(17–22). Early brain injury (EBI) refers to the damage ensuing in 
the first 72 h after the bleed caused by transient cerebral ischemia 
(CI), BBB disruption, edema, cell death, and brain tissue loss. 
Many of the patients who survive these phenomena deteriorate 
days later from delayed ischemic neurological deficit (DIND), 
which is responsible for poor outcomes or death in up to 30% 
of patients with SAH. DIND was traditionally attributed to nar-
rowing of the large basal cerebral arteries, termed cerebral or 
angiographic vasospasm, causing a reduction in cerebral blood 
flow (CBF) and, if critically reduced, progressing to infarction 
in the relevant vascular territory. However, a growing number of 
reports shows that angiographic vasospasm does not always cor-
relate with CI, cerebral infarction, or changes in CBF, indicating 
that DIND is a more complex (and complicated) phenomenon 
(23–33). The landmark CONSCIOUS-1 trial showed that an 
endothelin-1 antagonist ameliorates angiographic vasospasm, but 
fails to improve functional outcomes (34, 35), forever changing 
the concept of DIND, which is now suspected to arise from the 
combined effects of angiographic vasospasm, global reduction 
in blood flow, arteriolar constriction and thrombosis, cortical 
spreading depressions, and processes triggered by EBI (17–21, 36). 
With the complex interplay of the underlying pathological sub-
strates, DIND is often (incorrectly) used as a blanket term for 
vascular spasm, CI, and neurological (clinical) deficit. It remains 
unclear to what extent these phenomena overlap or represent 
distinct processes (Figure 2).
It is increasingly recognized that the neuroinflammatory 
cascade following SAH is the potential mechanistic link between 
the initial ictus and the progression of neuronal injury in EBI 
as well as the development of DIND (37–40). Both overlap-
ping phenomena of ischemic injury and vasospasm lead to an 
unfavorable physiological environment that may inflict neuronal 
injury (Figure 2), possibly driven in part by neuroinflammatory 
mediators.
Monitoring Neuroinflammation in the 
Neuro-Critical Care Unit (NCCU)
Patients suffering from TBI and SAH are typically treated in 
specialized NCCUs where extensive intracranial monitoring is 
implemented in order to detect subsequent secondary insults, 
prevent further deterioration, and optimize conditions for brain 
recovery (41, 42). Monitoring neuroinflammatory processes is 
technically and logistically complex, and this has hampered the 
development of pharmaceutical compounds that act to modulate 
the neuroinflammatory cascade (43). As we acquire a greater 
insight into the interplay between neuroinflammation and sec-
ondary brain injury, monitoring the neuroinflammatory events 
may open an opportunity to both increase our understanding of 
the molecular basis of the underlying pathology as well as identify 
novel therapeutic targets.
FigURe 1 | Conceptual summary of the neuroinflammatory response in acute brain injury. This illustration depicts some of the cellular and molecular sequelae and 
inflammatory cascades that occur following injury to the brain over time, divided into different compartments [cerebrospinal fluid (CSF), brain parenchyma, and 
vascular]. Initially, danger-associated molecular patterns (DAMPs) including double-stranded (ds)DNA, RNA, and brain-enriched proteins such as S100B provide 
early triggers to resident cells reflecting tissue injury and linking the initial insult to subsequent humoral and cellular cascades. These in turn lead to an increasingly 
cytotoxic environment promoting cellular responses, stimulating both immunocompetent cells in the central nervous system (resident microglia and astrocytes), as 
well as recruiting peripheral monocytes, through pattern recognition receptors (PRR) such as toll-like receptors (TLR). The secretion of cytokines, chemokines, and 
other potent chemotactic substances (including complement proteins) induces the recruitment of neutrophils and monocytes into the brain parenchyma through the 
increasingly permeable blood–brain barrier (BBB), as well as having a direct cytotoxic effect. Ongoing release of cytokines initiates a long-term inflammatory process, 
which allows the dynamic shift of macrophages and microglial canonical phenotype between M1 (classical activation) and M2 (alternative active presumably the 
result of antigen-presenting cells migrating from the periphery). These processes result in chronic inflammation as well as auto-immunization toward brain-enriched 
antigens. Key cytokines are highlighted in red. MBL, mannose-binding lectin; MASP, mannose-associated serine protease; MMP-9, matrix metalloproteinase 9.
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The aim of this narrative review is to demonstrate how dif-
ferent aspects of the neuroinflammatory response contribute to 
the pathophysiology of secondary brain injury. In addition, we 
discuss the methods available to monitor cellular and humoral 
inflammation in TBI and SAH patients in the clinical setting.
CYTOKiNe AND CHeMOKiNe 
MONiTORiNg iN ACUTe BRAiN iNJURY
There is no accepted gold standard in how to assess the neuroin-
flammatory processes in TBI and SAH. In clinical studies, the most 
common approach is to measure the concentration of cytokines 
and chemokines as biomarkers of ongoing neuroinflammation. 
Cytokines are small proteins of approximately 20 kDa molecular 
weight that are synthesized primarily by immune cells to pro-
mote and regulate inflammatory responses in an autocrine and 
paracrine fashion.
There are currently a wide range of commercially available 
assays that can detect with high sensitivity (pg/ml range) the 
levels of cytokines in different compartments. Historically, 
enzyme-linked immunosorbant assay has most frequently been 
used, but these require relatively large volumes of fluid/tissue 
and can only measure one cytokine at the time, and are therefore 
not ideal to monitor a complex inflammatory network. In the 
last 10 years, multiplex bead arrays have allowed the use of very 
small sample sizes (~25 μl per sample) to simultaneously measure 
several cytokines, thus greatly increasing the technical efficiency 
and our understanding of the inflammatory response in the 
injured brain (44).
CNS Compartmentalization of Cytokine 
Measurements
The CNS has several inherent barriers, restricting and control-
ling the flow of substances. These include the BBB, the blood–
cerebrospinal fluid (CSF) barrier, and the CSF–brain barrier. The 
brain compartment, or specifically the extracellular space of the 
brain, is accessible by using a microdialysis (MD) catheter. The 
MD catheter possesses a semipermeable membrane that is able 
to extract proteins like cytokines directly from the extracellular 
fluid (ECF) when inserted into the injured brain (13, 45).
FigURe 2 | Overlapping characteristics of the pathophysiology in 
subarachnoid hemorrhage (SAH). Simplified Venn diagram of the different 
pathophysiological processes that follow SAH. Rather than a linear 
relationship between vascular spasm, ischemia, and clinical deficit, these 
may be overlapping and also occur as distinct phenomena. Vascular spasm 
is most closely linked with endothelin-1-mediated vasoconstriction but may 
also encompass swelling of the vascular endothelium leading to an 
angiographic appearance of reduced contrast flow. Ischemia may result from 
an absolute reduction in blood flow, which may be complicated by local 
microvascular collapse or thrombosis, or even hyperemia causing localized 
swelling and reducing the capillary perfusion in that locality. Neurological 
deficits may be caused by frank ischemia and also result from phenomena 
such as cortical spreading depression.
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The CSF is produced by cells of the choroid plexus located 
within the cerebral ventricles and provides a medium to embed 
the brain, maintain a homeostatic environment, and facilitate the 
transport of nutrients and waste products. Thus, while using the 
CSF for cytokine measurement may provide a global assess-
ment of cerebral inflammation, it remains less specific in terms 
of regional monitoring. CSF is more easily accessible through, 
ideally, external ventricular drainage in sedated patients or via 
lumbar puncture in conscious patients where several milliliters 
can be drawn for analyses. While blood is biologically the most 
remote space from the organ of interest, it represents an easily 
accessible compartment for repeated sampling. To compare and 
monitor cytokine concentrations, collection of matched CSF and 
plasma samples over time allows a composite picture of ongo-
ing immune responses, distinguishing central from systemic 
cytokine profiles and determining how immune activation in the 
brain may impact on mechanisms occurring in the periphery and 
vice versa.
Figure 1 illustrates the intricate relationship between different 
compartments in the CNS and the potential cross-talk between 
the different compartments.
Cytokines in Blood
Although controversial, some groups have correlated cytokine 
concentrations measured in blood/plasma in the acute and 
chronic setting of patients with TBI and SAH to functional 
outcome (46–48). This suggests that, while these mediators may 
represent non-brain-specific inflammatory activity, systemic 
inflammation is triggered by brain injury, potentially having 
long-term sequelae such as stimulating an acute-phase response 
in the liver (49). Importantly, the pattern of cytokine production 
is both qualitatively and quantitatively different in blood com-
pared to CSF following injury (49–52), suggesting the existence 
of distinct biological processes at play.
Cytokines in CSF
Collection of CSF is the oldest and most prevalent method to 
test for inflammatory mediators following TBI and SAH and, and 
in contrast to blood sampling, it represents a global measure of 
cerebral immune activity. Access to ventricular CSF is achieved 
with surgical insertion of a drain in the ventricles to measure and 
monitor changes of intracranial pressure. Longitudinal measure-
ment of cytokines in CSF of patients with severe TBI reveals a 
biphasic immune response being maximal in the first few days 
after injury followed by a second modest increase by 7–10 days 
as shown for IL-6 (49).
These data have been confirmed using principal component 
analysis (PCA) of CSF cytokines and chemokines, resulting in 
the identification of distinct clusters of cytokine response (53, 54). 
Interestingly, multivariate analysis has also demonstrated a 
significant difference in outcome between the two clusters. Thus, 
assessing inflammatory activity provides a potential window for 
appropriate pharmaceutical therapies targeting cytokine produc-
tion (54). The difficulty is in disentangling the roles of individual 
mediators within these clusters to investigate rationalized treat-
ment targets.
In SAH, CSF samples may not be a true measure of neuroin-
flammation. The volume of blood present within the subarach-
noid space can affect the levels of cytokines present in CSF, and 
therefore, cytokine concentration in CSF is partly a consequence 
of the volume of SAH rather than a specific measure of the mag-
nitude of the inflammatory response within the brain.
Microdialysate Monitoring of Brain eCF
Microdialysis is inevitably a spatially restricted approach that 
can be used to target pericontusional/infarcted tissue at risk for 
secondary injury and thus allow us to monitor ongoing or wors-
ening focal brain damage. Notably, cytokine analysis revealed 
large variations in their concentrations when comparing CSF 
with brain-ECF (Table  1). However, the difference in cytokine 
levels between CSF and brain-ECF is smaller compared to the 
concentration gradients between these compartments and serum 
(55). Measurement of cytokines using MD have the additional 
complication of relative recovery. Relative recovery within 
the microdialysate fluid refers to the recovered fraction of the 
true concentration in the ECF, which is governed by a range of 
physicochemical factors including the molecular weight of the 
cytokine, its isoelectric point (which in turn determines the charge 
the protein carries at neutral pH and its solubility in water), and 
its native oligomerization characteristics (56). For some species, 
the relative recovery can be as low as 5% (exemplified in Table 1) 
making it technically difficult to reliably monitor.
There is an intricate interplay between the various cellular 
elements (both resident and recruited) within the brain, which 
TABle 1 | Comparison of selected cytokine concentrations in serum, CSF, and microdialysate in patients with traumatic brain injury.
Cytokine Mean recovered MD concentration 
from eCF (pg/ml)
RR (%) Mean recovered eCF 
concentration, adjusted for RR
Mean CSF 
concentration (pg/ml)
Mean serum concentration 
(pg/ml)
IL-1β 10.4–20.8 ~30% 34.6–69.3 9.9–89 0.5–7.4
IL-1ra 2,796 ~30% 9,320 26,861 10–221
VEGF 200.1 ~4% 5,003 26–43 37–773
Concentrations of interleukin-1 beta (IL-1β), interleukin-1 receptor antagonist (IL-1ra) and vascular endothelial growth factor (VEGF) in cerebrospinal fluid (CSF), serum and 
microdialysate (MD) from extracellular fluid (ECF). The relative recovery (RR, in %) is noted and adjusted for. Data from Ref. (56, 58).
5
Thelin et al. Monitoring Neuroinflammation in Acute Brain Injury
Frontiers in Neurology | www.frontiersin.org July 2017 | Volume 8 | Article 351
are both the source and target of these mediators (13, 57, 58), 
further complicating the interpretation.
Using either a qualitative approach or an unbiased quantita-
tive analysis (such as PCA), cytokine production appears as an 
intrinsic and ordered component among the multiple biochemical 
pathways contributing to delayed brain damage (57, 59). This fact 
would argue against the inflammatory response being a secondary 
form of injury per se, and rather a sequential cascade of molecular 
events [in the words of Julius Caesar: alea iacta est (the die is 
cast)], with a predetermined sequence following the initial injury.
Perfusate for Cytokine Recovery Using 
Microdialysis
MD is commonly used in the NCCU for metabolic monitoring 
of the injured brain, recovering small metabolites such as lactate, 
pyruvate, glucose and glycerol from the ECF (45). For these 
metabolites, the relative recovery is circa 70% from catheters 
inserted into the brain, using a flow rate of 0.3  µl/min (60). 
Importantly, the pore size of MD membranes used for metabolite 
analysis is significantly smaller (20  kDa) compared to the size 
used for larger proteins such as cytokines (100  kDa) (61, 62). 
By using 100 kDa cutoff catheters with the standard crystalloid 
solution, the relative recovery for cytokines has been shown to 
be typically 30%, but as low as 5% for cytokines that oligomerize 
(e.g., TNF) (56). In order to improve poor recovery rates, colloids 
such as human albumin solution (HAS) or dextran may be added 
to the perfusion fluid (63). The addition of colloids does not 
always improve the recovery of all cytokines; however, the relative 
recovery for TNF in 3.5% HAS has been shown to increase from 
4.4 to 31.2%, a sevenfold increase (56). A 3% Dextran-500 solu-
tion shows equally encouraging results compared to crystalloid 
solutions (64), and has the capacity to improve extraction of even 
larger inflammatory mediators (65, 66) and has been empirically 
demonstrated to remain within a 100  kDa membrane catheter 
(67). In summary, the optimal recovery of cytokines within the 
MD samples is dependent upon perfusate supplemented with 
albumin or dextran, favoring an improved relative recovery and 
no net loss of fluid from the catheter. In our opinion, this is an 
essential adjunct for protein microdialysis in general and specifi-
cally in recovering inflammatory mediators.
Statistical Approaches to Cytokine Studies
While the neuroinflammatory cascade following TBI is complex 
and characterized by substantial collinearity and functional 
overlap among mediators, many studies have focused on single 
cytokines utilizing univariate comparative statistics without 
adequately assessing the interrelationships with other factors 
(68–70). A more appropriate statistical approach would be to 
incorporate several cytokines into multivariate analysis methods, 
such as PCA (71). By using PCA, it is possible to detect the great-
est sources of variance in the dataset and thus highlight patterns 
in the cytokine response (59). A regression extension of PCA 
such as partial least square discriminant analysis (PLS-DA) can 
be used to identify variations in a particular domain such as time 
(58, 72). PLS-DA has the disadvantage of introducing bias, but 
can be used to test prespecified hypotheses.
interpretations of Cytokine Studies in TBi
A systematic review has identified 32 studies describing the 
analysis of CSF cytokines in 1,363 severe TBI patients, of which 
19 studies reported the analysis of cytokines via MD in 267 severe 
TBI patients (73). The majority of the MD studies have been pub-
lished from a few centers of excellence in TBI research, known 
for their work in the field of cerebral MD. From these studies, it 
is evident that MD catheter positioning plays a crucial role in 
the amount of cytokines recovered, with peri-lesional or lesional 
locations displaying greatly different cytokine profiles compared 
to “healthy” non-lesioned tissue. There is also a stereotyped 
response to injury whereby the peaks of MD derived cytokines 
such as interleukin-1 beta (IL-1β), IL-6, and IL-8 occur within the 
first 48–72 h post-TBI, with IL-10 remaining elevated through-
out the acute period up to 5  days of monitoring. Therapeutic 
modulation of the neuroinflammatory response to TBI has been 
demonstrated clinically in patients using subcutaneous admin-
istration of recombinant human IL-1 receptor antagonist, with 
the aim of attenuating the experimentally proven IL-1-mediated 
cellular damage in the injured brain (57, 58). Several studies 
have attempted to correlate CSF cytokine concentrations [IL-1β, 
interleukin-1 receptor antagonist (IL-1ra), IL-6, IL-8, IL-10 and 
TNF] with patient outcome, demonstrating a number of con-
flicting data [summarized in a review article (74)]. We would 
argue that this approach is flawed as it ascribes a unitary role 
for a given cytokine (as “good” or “bad”) as well as ignoring the 
high degree of collinearity between all these mediators (75). It is 
important to recognize the delicate interplay between mediators 
such that the ultimate effect of a given cytokine is determined by 
the specific cellular, chemical, and temporal milieu in which the 
cytokine is acting. Finally, the clinical complication profile with 
brain-ECF and CSF-based cytokine sampling appears to be quite 
low, attesting to the safety of both procedures in critically ill TBI 
patients. All these findings are necessarily limited by the small 
number of studies identified in the accompanying systematic 
review.
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interpretations of Cytokine Studies in SAH
Similar to the findings identified in the review on TBI, the stud-
ies reporting on the analysis of cytokines via MD and CSF in 
aneurysmal SAH cytokine can be found in the parent systematic 
review, included in this Research Topic in Frontiers in Neurology 
(Zeiler et  al., 2017, II submitted). Overall, there are 9 studies 
describing the analysis of cytokines via MD in 246 aneurysmal 
SAH patients. Another 20 studies reported the analysis of CSF 
cytokines in 630 patients. As with the TBI cytokine literature, the 
MD and CSF studies identified within the review originated from 
a small number of centers of excellence in NCCU and SAH based 
research. This body of literature is smaller than that identified 
within the TBI population. Thus, the conclusions that can be 
made within the SAH systematic review are somewhat limited. 
However, as with the TBI literature, some interesting trends 
should be highlighted. Again, MD catheter location plays a role 
in the cytokine levels obtained in SAH patients, with lesioned 
tissue (i.e., ICH, ischemic brain) and peri-lesional tissue display-
ing higher cytokine levels than the “healthy” non-lesioned tissue. 
Second, SAH patients displayed peaks in MD IL-1β, IL-6, and 
IL-8 within the first 12  h’ post-hemorrhage, while (as in TBI) 
IL-10 appears to remain elevated within the acute period. Third, 
CSF-based cytokines in SAH appear to correlate with patient 
outcome, but as with the TBI data, our interpretation is that this 
type of solitary comparative analysis for each given cytokine 
may be misleading as there will be a potent collinearity between 
all these mediators. The association between cytokine profiles 
and the incidence of clinical vasospasm post-SAH has been 
documented in a previous systematic review and meta-analysis, 
with IL-6 and TNF linked to the development of vasospasm and 
delayed ischemic neurological deficit (DIND) (76). In addition, 
chronic hydrocephalus and shunt dependency may be associated 
with TGF-β levels within the CSF for SAH patients.
TiSSUe SAMPliNg TO ASSeSS 
NeUROiNFlAMMATiON
A direct method to determine focal inflammatory activity is to 
biopsy samples adjacent to the injured tissue. Compared to indirect 
sampling of fluid, this provides a measure of tissue inflammation 
with a high degree of confidence; however, it remains a temporal 
snapshot that cannot readily reflect dynamic processes. Harish 
et al. found that surgically removed tissue demonstrates higher 
concentrations of several, predominantly pro-inflammatory, 
cytokines, and chemokines in contused brain vs pericontusional 
tissue (77). They also found a high degree of macrophage and 
microglia activity in contused regions, suggesting strong inflam-
matory activity. Similarly, Bellander et  al. identified increased 
complement activation from pericontusional tissue (78), indicat-
ing a strong inflammatory response, especially in surrounding 
neurons, following TBI. Additionally, in postmortem tissue of 
TBI patients, it has been shown that pro-inflammatory cytokine 
mRNA and protein concentration are significantly elevated com-
pared to cytokines with a more anti-inflammatory function (79). 
In the same study, regions with a profound cytokine production 
were associated with abundant inflammatory cell infiltration, 
astrogliosis, and axonal pathology. While in postmortem tissue, 
changes that occur at the time of death might influence results, 
this study directly demonstrates that cytokines are upregulated in 
the brain parenchyma as early as a few minutes from brain injury. 
In the future, it might be possible to directly assess the inflamma-
tory profile of the brain by acquiring brain tissue samples.
iMAgiNg TeCHNiQUeS TO MeASURe 
THe NeUROiNFlAMMATORY ReSPONSe
Advances in neuroimaging have allowed aspects of the neuroin-
flammatory cascade to be assessed with a high degree of spatial 
resolution. Ideally, these techniques can be combined with other 
tools such as MD, which are focal but provide temporal resolu-
tion, to get a more complete overview of inflammatory processes.
Positron emission Tomography (PeT)
Positron emission tomography relies on radioligands, which bind 
to a specific receptor or mimic a biological molecule of interest, 
and can be used in in  vivo studies of neuroinflammation (80). 
Translocator protein (TSPO) is a 18  kDa mitochondrial mem-
brane protein involved in steroid biosynthesis and is by far the 
most studied target to quantify microglial activation following 
TBI (81, 82). The first-generation TSPO ligand, [11C]-PK11195 
is the most commonly employed; however, there are now several 
second-generation agents with improved signal to noise ratio and 
reduced non-specific binding. The second-generation agents all 
demonstrate variable binding between individuals relating to a 
specific genetic polymorphism resulting in different TSPO affin-
ity for the radiolabeled ligands (83). PET studies have revealed 
that the binding of TSPO ligand PK-11195 remains elevated 
chronically, many years following TBI (81, 82), and that the 
degree of binding, and therefore chronic microglial activation, 
correlates with the degree of cognitive impairment (81). The 
second-generation TSPO ligand [11C]DPA-713 has been used 
to demonstrate cellular neuroinflammation in retired American 
football players (84, 85).
Translocator protein ligands are limited by their overexpres-
sion in reactive astrocytes, complicating the interpretation of 
the resulting binding (86, 87). Moreover, expense and the abil-
ity to generate radioligands on-site in the acute phase make the 
logistics of scanning complex. Nevertheless, currently, TSPO PET 
remains the only method for human in vivo imaging of microglial 
activation.
Other putative PET ligands to assess neuroinflammation 
include cannabinoid-2-receptor (88), cyclo-oxygenase (COX) 
(89), and matrix metalloproteinases (90) but these have not 
been adequately studied in acute brain injury. Furthermore, it is 
also possible that (18F)-FDG-PET may be applicable to imaging 
neuroinflammation, because of the apparent linkage between 
metabolic programing and inflammation (see below).
Magnetic Resonance imaging (MRi)
The clinically used MRI sequences may be used to explore specific 
features of neuroinflammation (91), most commonly by assess-
ing BBB integrity through the addition of the contrast agent 
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Frontiers in Neurology | www.frontiersin.org July 2017 | Volume 8 | Article 351
gadolinium (92). In preclinical experimental settings, there are 
more advanced MRI applications, employing microparticles iron 
oxide, endothelial vascular cell adhesion molecule-1 (VCAM-1) 
(93), and macrophage-specific epitopes (94). However, in clinical 
studies in humans, MRI has not been employed to directly assess 
neuroinflammation, rather indirectly provide a measure of BBB 
dysfunction and endothelial cell activation.
Magnetic Resonance Spectroscopy (MRS)
The prevalent form of in  vivo spectroscopy is 1H magnetic 
resonance spectroscopy (1H-MRS, also called proton MRS). 
This is employed to assess relative levels of cerebral metabolites. 
MRS is also known as NMR spectroscopy, but usually the term 
MRS refers to in  vivo measurements and NMR to ex vivo or 
in  vitro measurements. The most abundant signal in the brain 
1H spectrum is usually N-acetylaspartate (NAA). The peptide 
N-acetylaspartylglutamate (NAAG) is a product of NAA and 
the two are interconvertible. NAAG is a small peak in the brain 
1H-MRS that is difficult to distinguish from NAA. Often both 
are considered together as “total NAA” that is interpreted as a 
marker for neuronal health, viability, and/or number of neurons, 
particularly their mitochondria. Reduction in NAA is regarded 
as indicating dysfunction (permanent or temporary) of neuronal 
tissue. Other 1H signals include creatine (combined signal 
from creatine and phosphocreatine), glutamate and glutamine 
(often considered together as Glx as the two species’ signals are 
incompletely resolved), gamma-aminobutyric acid, and lactate. 
1H MRS also allows detection of elevated levels of myo-inositol 
(osmolyte present in glial cells) and choline containing com-
pounds. Commonly, MRS is used to measure metabolic activity 
in TBI (95), but these substances have also been shown to act as 
a surrogate of neuroinflammation (91, 96).
Another form of MRS less commonly used is 13C-MRS, which 
necessitates administration (usually intravenously, or sometimes 
orally) of substrates such as glucose, acetate, lactate etc. that have 
been manufactured to be artificially enriched in 13C (e.g., 99%), 
in contrast to the natural abundance of 13C that is only 1.1% of 
all carbons. 13C-MRS methodology is a powerful means of quan-
tifying metabolic fluxes in vivo, e.g., the tricarboxylic acid cycle 
and glutamate–glutamine cycling (97). Also, in recent years, 13C 
hyperpolarization has evolved, a technique that boosts the 
13C-MRS signal albeit for a very brief duration. Clinically, it utilizes 
hyperpolarized 1-13C pyruvate, given intravenously, to measure 
glycolysis vs TCA cycle, by means of signals for the respective 
products 1-13C lactate and 13C HCO3− (98). To date, it has mostly 
been used to image tumors (99), although results have emerged 
recently on 13C hyperpolarization in preclinical TBI (100, 101). 
13C-MRS modalities may be useful in future in studies of neuro-
inflammation. A recent development (preclinically) is the use of 
hyperpolarized [6-13C] arginine to detect inflammatory cell func-
tion in cancer (102), and this could presumably be used in brain 
injury. A final MRS modality is 31P-MRS. No artificial enrichment 
is needed as 31P is virtually 100% of all naturally occurring phos-
phorus atoms. 31P-MRS is not commonly used, despite being able 
to measure energy-related phosphorus species non-invasively 
in  vivo, including phosphocreatine, ATP, and inorganic phos-
phate. Notably, in a 31P-MRS study of TBI patients, Garnett et al. 
(103) suggested that the changes (vs healthy controls) might be 
due to reactive gliosis in the injured brain. The 31P-MRS modality 
is being actively investigated in acute brain injury.
THe ADAPTive iMMUNe SYSTeM
In comparison to the innate immune system, the adaptive immune 
response has not been as extensively studied. It is believed that 
the transition between the innate and adaptive immune response 
following acute brain injury is moderated by migrating antigen-
presenting dendritic cells (104).
Cellular Components of the Adaptive 
immune Response
The cellular components of the adaptive immune system can 
be measured in blood by identifying specific subpopulations of 
peripheral lymphocytes using flow cytometry. In severe TBI, this 
technology has revealed that the number of T-cells, specifically 
CD8+ cytotoxic cells, decrease significantly following TBI, while 
the number of B-cells remain constant (105).
Autoimmune Responses to Neural 
Antigens
The humoral adaptive immune system is also activated following 
TBI as a result of presentation of previously novel neural antigens 
to the peripheral immune system. Acute brain injury triggers the 
production of autoantibodies toward brain-specific proteins, 
including the brain-enriched proteins glial fibrillary acidic 
protein (106) and S100B (107). Moreover, Cox and coworkers 
showed that peripheral blood mononuclear cells isolated from 
patients with TBI have the capacity to proliferate in vitro when 
stimulated by myelin basic protein, the most abundant protein 
of the myelin sheath expressed in the brain by oligodendrocytes 
(108).
These adaptive responses are long lasting and are a candidate 
mechanism in the later stages of the pathophysiology of brain 
injury that may underlie chronic neurodegeneration (109); 
however, the mechanism by which empirically identified autoan-
tibodies inflict neuronal injury is yet to be proven.
FAilURe OF CliNiCAl TRiAlS USiNg 
“ANTi-”iNFlAMMATORY AgeNTS
There have been numerous failures to translate promising 
preclinical agents targeting the underlying conditions in brain 
injury studies into efficacious phase III human studies (110). 
Several reasons for this have been suggested, including small 
group sizes, inadequate dosing, inappropriate delivery route, 
inadequate therapy duration, and timing of drug delivery in 
relation to the occurrence of injury [several of the suggested 
harmful pro-inflammatory cytokines are elevated predomi-
nantly the first hours after injury (13)], the complexity of BBB 
and adequate drug penetration. In fact, large phase III studies, 
including corticosteroids (CRASH trial) (111), progesterone 
(112, 113), and erythropoietin (114) failed to detect the presence 
of the administered drug in the brain, something that could have 
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been determined empirically using microdialysis (45). Moreover, 
due to poor penetration of pharmacological compounds across 
the BBB, lower concentrations of the drug may have reached 
the brain explaining the lack of expected neuroprotection (115). 
Before deciding to embark on large phase III ventures, which are 
costly and consume much time and resources, adequate phase 
II clinical studies with informative surrogate endpoints should 
be performed, including microdialysis, to ascertain the degree to 
which the drug can cross the BBB and exert changes on relevant 
biomarkers, including immune response-related molecules such 
as cytokines and chemokines.
CONCePTUAl UNDeRSTANDiNg OF 
MeCHANiSM OF ACTiON
Within recent years, there have been several ongoing trials aimed 
at negating the neuroinflammatory response in brain injury (43). 
As we improve the monitoring of the inflammatory response, 
we can improve the accuracy of prediction of how new anti-
inflammatory drugs impact on the innate inflammatory response, 
and when they should be delivered, in order to best modulate 
neuroinflammation following brain injury. However, improved 
monitoring techniques also lead to increased study complexity 
as more data become available. Helmy and coworkers treated 10 
patients with an IL-1ra (Anakinra) and they demonstrated that 
the cytokine response in ECF in the treated group resembled 
that of the classical pro-inflammatory microglial activation (M1) 
(116), with increased IL-1β and low levels of IL-4 and IL-10. These 
findings were counterintutitive given the classification of IL1ra as 
an “anti-inflammatory cytokine” and therefore more in keeping 
with the M2 (anti-inflammatory, adaptive) response that would 
have led to a predominance of anti-inflammatory cytokines (57). 
Nevertheless, the more data we obtain from the complex cascades 
in the neuroinflammatory response, the greater the refinement 
in our understanding. There is an increasing recognition that 
microglia and macrophages have the capability to express both 
M1 and M2 specific phenotypes (117), and that the classification 
system does not accurately reflect the complexity of microglial 
function (118).
Over recent years, the idea of metabolic reprogramming of 
macrophages associated with inflammatory phenotype has 
gained ground. Very recently, a study by Ip et al., in the context 
of inflammatory bowel disease, has shown that IL-10 opposes 
the switch to the more glycolytic metabolic program induced by 
inflammatory stimuli in macrophages (119). Specifically, IL-10 
inhibits lipopolysaccharide-induced glucose uptake and gly-
colysis and promotes oxidative phosphorylation. These findings 
may be relevant to harnessing metabolic reprogramming to treat 
inflammation in injured brain.
CHRONiC SeQUelAe OF 
NeUROiNFlAMMATiON
Following brain injury, a chronic inflammatory state has been 
shown to correlate to several clinical conditions. One of the most 
common symptoms decreasing quality of life in patients that suffer 
from TBI is post-traumatic depression (PTD), which is present in 
up to 44% of patients (120). A study reported that higher levels 
of the acute CSF endothelial markers (sVCAM, sICAM-1, and 
sFAS) as well as IL-7 and IL-8, were associated with PTD as 6 and 
12 months post-TBI, respectively (121).
Chronic traumatic encephalopathy (CTE) is a neurodegen-
erative condition leading to impairments in mood, behavior, 
cognition, and motor functioning and predominantly affecting 
patients with mild, repetitive TBI, common in contact sports 
(122). CTE has been defined as a tauopathy where phosphoryl-
ated tau accumulates within cells in the CNS (123). Recently, a 
cadaver study highlighted the presence of activated microglia 
(CD68-positive cells) close to tau deposits (124).
Another common complication following TBI is epilepsy 
(125), occurring in up to 20% of patients. Similarly, following 
SAH, a prevalence of between 7 and 25% has been reported 
(126, 127). Diamond et al. (128) found that a high CSF/plasma 
IL-1β ratio correlated with post-traumatic epilepsy (PTE) 
and that presence of a specific single-nucleotide peptide of 
the IL-1β gene (rs1143634) correlates with a higher risk of 
PTE following brain injury. Claassen and coworkers found 
an association between the inflammatory response follow-
ing SAH (TNF-receptor 1 and high-sensitivity C-reactive 
protein) and the presence of seizures (129). Several reviews 
covering this field have been published, and all do suggest a 
strong link between neuroinflammatory cascades, increased 
excitotoxicity, and epileptogenesis in the aftermath of brain 
injury (130, 131).
It may therefore be possible to target inflammatory mediators 
after TBI and SAH, to alleviate the burden of these associated 
long-term morbidities.
COlliNeARiTY AND CONFOUNDiNg 
FACTORS BeTweeN iNFlAMMATORY 
MeDiATORS
Collinearity is a statistical term that describes how two (or more) 
variables correlate with each other to a high degree. As most 
inflammatory mediators are present at a low concentration in the 
uninjured brain, and the subsequent increase in concentration 
is a response to injury, they are likely to correlate with injury 
severity. It is therefore not surprising that many of the mediators 
can correlate with outcome and this may be confounded by the 
severity of injury, rather than a specific facet of the biology of the 
mediator of interest.
This is further complicated by the fact that most studies focus 
on a small panel of mediators such as the “pro”-inflammatory 
mediators such as IL-1β, IL-6, TNF, and IFN-γ as well as “anti”-
inflammatory cytokines IL-4 and IL-10. However, we should 
not discount the importance of other unmeasured mediators in 
contributing to the detrimental inflammatory responses after 
TBI and SAH. Cytokines are known to act in complex cascades 
with some early potent mediators that subsequently trigger the 
synthesis of regulatory cytokines which act to temper the ini-
tial response. Although in some cases cytokines have partially 
overlapping functions, each cytokine has a unique role, pattern 
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of expression, and cellular source. Moreover, cytokines and 
chemokines display effects that are both “damaging” and “repara-
tive” that may occur simultaneously in the post-injury phase (57). 
This dual effect has been also acknowledged for microglia and 
macrophages as both play both a beneficial and detrimental role 
in the injured brain (9, 14).
COMBiNATiON THeRAPY
Biological redundancy in complex interrelated systems means that 
there are multiple pathways to secondary neuronal injury (45). 
However, in most clinical trials, only a single therapy is used to 
target a single pathway limiting the potential efficacy. This is a 
TABle 2 | Limitations in current neuroinflammation literature.
issues limitations Suggested approaches
Biological compartments Brain-ECF best for receptor and brain tissue biology, while 
CSF easier to collect and available in larger volume. Both 
feasible only short term. Blood is readily accessible for any 
injury severity, multiple sampling possible but less specific for 
brain pathology. Direct tissue sampling has the highest spatial 
resolution but difficult to acquire
Combining multiple samples, microdialysate has specific advantages 
for drug studies but should be combined with serum/CSF to reflect the 
global production of mediators
Monitoring time frame Varying time-frames to insult, some neuroinflammatory 
cytokines have brief early temporal profiles and thus late 
monitoring may miss some biological signals
 – Correct to time of injury
 – Beware false negatives
 – Late inflammatory monitoring (6–12 months) is associated with 
chronic sequelae
Collinearity and confounding Several studies only measure a small number of mediators and 
are thus inferring causation incorrectly as other mediators may 
confound results
 – Multivariate statistics are necessary
 – Need to measure multiple mediators simultaneously to avoid bias
 – Interventional studies required to infer causation
Regional vs global monitoring Signal to noise ratio with dilution of mediators vs missing focal 
lesions. How representative is the data?
Combinatorial approaches, e.g., focal monitoring, global biomarkers, 
and neuroimaging
Microdialysis methodology Protein microdialysis requires specific approaches to improve 
relative recovery
 – Dextran or albumin should be used as carriers to increase relative 
recovery
 – Sensitive assays necessary as low concentrations are common
 – Multiplex technology allows simultaneous measurement of several 
cytokines
Clinical follow-up Clinical outcome metrics such as Extended Glasgow Outcome 
Scale, SF36 may be insensitive and fail to capture subtle 
neurocognitive sequelae
Several modalities of outcome assessment necessary after as long as 
12 months after ictus, including
 – Cognitive
 – Neuropsychological
 – Quality of life
 – Psychiatric
 – Functional outcomes
Neuroimaging Difficulties in inferring what NMR, and TSPO PET binding 
represents at cellular level in relation to neuroinflammation
Combinatorial approaches necessary for future research, e.g., focal 
microdialysis monitoring plus neuroimaging
Systemic injury Polytrauma might contribute to peripheral inflammatory 
response, which may modify or overlap with central 
neuroinflammatory response
 – Accurate definition of patient population and injury assessment
 – Measurement of brain compartments vs extracranial components
Tissue outcomes Difficult to access tissue samples unless associated with a 
surgical procedure
Tissue biopsies present a way to accurately describe the focal 
inflammatory response. Can complement other techniques
Autoimmune response Empirical evidence that the adaptive immune system involved, 
but not clear if epiphenomenon or causative in inflicting 
neuronal injury
 – Relating innate to adaptive immunity is developing field
 – Issue of cellular elements vs humoral
SAH neuroinflammation Several pathological entities can overlap: early brain 
injury, vascular spasm, tissue ischemia each with its own 
neuroinflammatory signature
Careful characterization of the clinical state at the time of monitoring
Preclinical experiments Molecular and cellular events that drive neuroinflammatory 
responses in the acute and chronic phases in traumatic brain 
injury requires animal or in vitro models for better bed-to-bench 
side translational research
 – Systematic consideration of age, weight, species, sex to highlight 
variations in the neuroinflammatory response
 – Large animal models necessary to replicate human injury patterns 
(gyrencephalic brain, greater volumes for sampling etc.)
 – Improved outcome metrics that are adequate representations of 
human conditions
 – Better collaborations between clinicians and preclinical researchers 
to address the caveats in current research paradigms
Table illustrating current issues, limitations, and suggested approaches.
MD, microdialysis; CSF, cerebrospinal fluid; SF36, short form questionnaire 36; NMR, nuclear magnetic resonance; TSPO, translocator protein; PET, positron emission tomography; 
SAH, subarachnoid hemorrhage.
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potential reason why there is still no approved drug that has shown 
any clinical efficacy in mitigating neuronal injury in TBI and SAH. 
However, polytherapy using preclinically proven neuroprotective 
drugs (i.e., progesterone and Vitamin D hormone, creatinine, 
and choline) has also failed to show any treatment benefit (132), 
presumably as there are fundamental pathological differences 
between animal models and human brain injury (133) and also 
because we need a better understanding of the underlying patho-
physiology and how the different pharmacological agents interact.
Nonetheless, a review of agents negating the neuroinflam-
matory cascades in brain injury indicates that there are many 
promising pharmaceutical agents currently being developed (43). 
Furthermore, with the tools currently available, it is increasingly 
feasible to monitor the neuroinflammatory response to therapy, 
thus allow researchers to rationalize specific combinations of 
therapy.
CHAlleNgeS AHeAD
There are several challenges and limitations in the field today. 
The major issues surrounding these techniques discussed in this 
manuscript are summarized in Table 2.
To measure and assess inflammatory activity, several cur-
rent studies investigate a single marker in a single biological 
compartment. As discussed above, to adequately understand the 
neuroinflammatory response requires combinations of method-
ologies looking at multiple down-stream cytokines (59, 121), but 
also region specific focal inflammatory activity using PET-MRI 
(81, 82) and T-cell mediated autoreactivity toward brain-specific 
proteins (108).
Moreover, more sophisticated biostatistical methods analo-
gous to the “-omic”-literature are required. Multivariate methods 
incorporating the entire cytokine profile using tools such as 
principal component analyses will presumably be necessary until 
we reach a greater understanding of these processes (57, 59).
In summary, we suggest a multimodal approach for the meas-
urement of cytokines in various fluids, parallel to neuroimaging 
techniques to visualize changes in cellular/microglia activation 
with repeated measurement of both humoral and cellular 
immune activation to distinguish acute from chronic responses. 
Only this holistic approach will provide a deeper understanding 
of the longitudinal inflammatory processes in hope to develop 
accurately targeted and efficacious anti-inflammatory therapies.
CONClUSiON
The neuroinflammatory cascade following TBI and SAH 
comprises a wide array of both humoral and cellular players. 
An ever-growing literature has defined changes in cytokine 
production and cell activation in both the acute and chronic 
phases following brain injury. However, we are still confronted 
with the difficulty in placing the individual components into 
a coherent picture. The extended time course of inflammation 
following these conditions provides multiple opportunities for 
therapeutic intervention. However, there is a limit to what we 
can learn from observational clinical studies as to the role of 
individual mediators/cells and ultimately understand how they 
affect patient functional outcome. For this reason, it is pivotal 
to maintain a close dialog between clinical and experimental 
research, in order to identify the distinct role of cytokines and 
immune cells, acting in the large scheme of the complex inflam-
matory responses.
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